PainReform (PRFX) 20-F 16 Mar 22 2021 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2021shares
Document Type	20-F
Entity Registrant Name	PAINREFORM LTD
Document Fiscal Period Focus	FY
Document Period End Date	Dec. 31, 2021
Entity Well-known Seasoned Issuer	No
Entity Shell Company	false
Entity Central Index Key	0001801834
Entity Filer Category	Non-accelerated Filer
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Incorporation, State or Country Code	L3
Document Fiscal Year Focus	2021
Entity Emerging Growth Company	true
Entity Voluntary Filers	No
Entity File Number	001-39481
Document Annual Report	true
Entity Common Stock, Shares Outstanding	10,482,056
Entity Interactive Data Current	Yes
Trading Symbol	PRFX
Security Exchange Name	NASDAQ
Entity Ex Transition Period	true
Title of 12(b) Security	Ordinary shares, par value NIS 0.03 per share
Entity Address, City or Town	Tel Aviv
Entity Address, Address Line One	65 Yigal Alon St.,
Entity Address, Postal Zip Code	6744316
Entity Address, Country	IL
Document Accounting Standard	U.S. GAAP
Document Registration Statement	false
Document Shell Company Report	false
ICFR Auditor Attestation Flag	false
Document Transition Report	false
Auditor Firm ID	1197
Auditor Location	Tel Aviv, Israel
Auditor Name	Brightman Almagor Zohar & Co
Kesselman & Kesselman [Member]
Auditor Firm ID	1309
Auditor Location	Tel-Aviv, Israel
Auditor Name	Kesselman & Kesselman
Business Contact [Member]
Contact Personnel Email Address	ihadar@painreform.com
Entity Address, City or Town	Tel Aviv
Entity Address, Address Line One	65 Yigal Alon St.
Contact Personnel Name	Ilan Hadar
Entity Address, Postal Zip Code	6744316
Entity Address, Country	IL

BALANCE SHEETS

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 16,537	$ 15,677
Restricted cash	34	13
Prepaid clinical trial expenses and deferred clinical trial costs	1,728	1,294
Prepaid expenses and other current assets	721	807
Total current assets	19,020	17,791
Property and equipment, net	53	10
Total assets	19,073	17,801
Current liabilities:
Trade payables	136	720
Employees and related liabilities	423	92
Accrued expenses	198	149
Total current liabilities	757	961
Non-current liabilities:
Provision for unrecognized tax positions	234	220
Total non-current liabilities	234	220
Total liabilities	991	1,181
Commitments and contingencies
Shareholders' Equity:
Ordinary shares, NIS 0.03 par value; Authorized: 26,666,667 and 16,666,667 shares as of December 31, 2021 and 2020, respectively; Issued and outstanding: 10,482,056 and 8,758,037 shares as of December 31, 2021 and 2020, respectively;	94	78
Additional paid-in capital	41,715	33,023
Accumulated deficit	(23,727)	(16,481)
Total shareholders' equity	18,082	16,620
Total liabilities, shareholders’ equity	$ 19,073	$ 17,801

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) $ in Thousands	Dec. 31, 2021₪ / sharesshares	Dec. 31, 2020₪ / sharesshares
Statement of Financial Position [Abstract]
Ordinary shares, par value (in New Shekels per share) | (per share)	₪ 0.03	₪ 0.03
Ordinary shares, shares authorized	26,666,667	16,666,667
Ordinary shares, shares issued	10,482,056	8,758,037
Ordinary shares, shares outstanding	10,482,056	8,758,037

STATEMENTS OF COMPREHENSIVE LOS

STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
Research and development expenses		$ (2,860)	$ (354)	$ (136)
General and administrative expenses		(4,348)	(1,317)	(553)
Operating loss		(7,208)	(1,671)	(689)
Financial expense, net		(32)	(2,162)	(590)
Loss before taxes		(7,240)	(3,833)	(1,279)
Tax expenses		(6)	(220)	0
Net loss and comprehensive loss		$ (7,246)	$ (4,053)	$ (1,279)
Basic and diluted net loss per share	[1]	$ (0.74)	$ (1.25)	$ (4.17)
Weighted average number of shares of ordinary share used in computing basic and diluted net loss per share	[1]	9,812,234	3,243,943	576,556
[1]	Share and per share data is presented on a retroactive basis to reflect the reverse share split, refer to note 1(c).

STATEMENT OF CHANGES IN SHAREHO

STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Convertible preferred shares (Temporary equity) [Member]	Ordinary shares [Member]	Additional Paid-in Capital [Member]	Accumulated deficit [Member]	Total
Balance at Dec. 31, 2018	$ 6,621	$ 5	$ 66	$ (11,149)	$ (11,078)
Balance, shares (in Shares) at Dec. 31, 2018	2,954,267	576,556
Share-based compensation to employees	$ 0	$ 0	89	0	89
Share-based compensation to employees, shares ( in Shares)	0	0
Share-based compensation to service providers					0
Operating lease provided by controlling shareholder	$ 0	$ 0	25	0	25
Net loss and comprehensive loss	0	0	0	(1,279)	(1,279)
Balance at Dec. 31, 2019	$ 6,621	$ 5	180	(12,428)	(12,243)
Balance, shares (in Shares) at Dec. 31, 2019	2,954,267	576,556
Conversion of preferred shares into ordinary shares	$ (6,621)	$ 26	6,595	0	6,621
Conversion of preferred shares into ordinary shares (in Shares)	(2,954,267)	2,954,267
Conversion of convertible notes into ordinary shares	$ 0	$ 25	7,135	0	7,160
Conversion of convertible notes into ordinary shares (in Shares)	0	2,727,214
Share issuance under Initial Public Offering, net	$ 0	$ 22	17,288	0	17,310
Share issuance under Initial Public Offering, net (in Shares)	0	2,500,000
Equity classification of a derivative warrant liability (Note 6(b))		$ 0	1,552	0	1,552
Share-based compensation to employees	$ 0	$ 0	38	0	38
Share-based compensation to employees, shares ( in Shares)	0	0
Share-based compensation to service providers	$ 0	$ 0	202	0	202
Share-based compensation to service providers, shares	0	0
Operating lease provided by controlling shareholder	$ 0	$ 0	33	0	33
Net loss and comprehensive loss	0	0	0	(4,053)	(4,053)
Balance at Dec. 31, 2020	$ 0	$ 78	33,023	(16,481)	16,620
Balance, shares (in Shares) at Dec. 31, 2020	0	8,758,037
Share-based compensation to employees and directors	$ 0	$ 0	812	0	812
Share-based compensation to employees and directors (in shares)	0	0
Share-based compensation to service providers	$ 0	$ 0	412	0	412
Share-based compensation to service providers, shares	0	0
Shares and warrants issuance - Private Investment in Public Equity ("PIPE"), net	$ 0	$ 12	5,542	0	5,554
Shares and warrants issuance - Private Investment in Public Equity ("PIPE"), net (in shares)	0	1,304,346
Exercise of warrants	$ 0	$ 4	1,926	0	1,930
Exercise of warrants (in shares)	0	419,673
Net loss and comprehensive loss	$ 0	$ 0	0	(7,246)	(7,246)
Balance at Dec. 31, 2021	$ 0	$ 94	$ 41,715	$ (23,727)	$ 18,082
Balance, shares (in Shares) at Dec. 31, 2021	0	10,482,056

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020		Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (7,246)	$ (4,053)		$ (1,279)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	7		[1]	1
Operating lease provided by controlling shareholder	0	33		25
Share-based compensation to employees	812	38		89
Share-based compensation to service providers	412	202		0
Interest expense and amortization of discount on convertible notes	0	987		541
Issuance costs	0	0		47
Revaluation of derivative warrant liability	0	1,105		2
Change in:
Other current and non-current assets	(348)	(1,884)		(183)
Trade payables	(585)	720		(2)
Other accounts payable and accrued expenses	395	295		150
Net cash used in operating activities	(6,553)	(2,557)		(609)
Cash flows from investing activities
Purchase of property and equipment	(50)	(10)		0
Net cash used in investing activities	(50)	(10)		0
Cash flows from financing activities
Proceeds from issuance of convertible notes, net	0	0		241
Proceeds from exercise of warrants	1,930	0		0
Proceeds from issuance of ordinary shares under Private Investment in Public Equity	6,000	0		0
Issuance costs	(446)	0		0
Proceeds from issuance of August and December 2019 convertible notes and warrants, net	0	0		1,269
Proceeds from issuance of ordinary shares under Initial Public Offering, net		17,310
Net cash provided by financing activities	7,484	17,310		1,510
Change in cash, cash equivalents and restricted cash	881	14,743		901
Cash, cash equivalents and restricted cash at the beginning of the year	15,690	947		46
Cash, cash equivalents and restricted cash at the end of the year	$ 16,571	$ 15,690		$ 947
[1]	Represents amount less than $1

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2021
Compensation Related Costs [Abstract]
GENERAL	NOTE 1:- GENERAL a. PainReform Ltd. ("the Company") was incorporated and started business operations in November 2007. The Company is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. The Company’s proprietary extended release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. b. Liquidity Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical trials, and capital raising activities. The Company is still in its development and clinical stage and has not yet generated revenues. The Company has incurred losses of $7,246, $4,053 and $1,279 for the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, the Company’s accumulated deficit was $23,727. The Company has funded its operations to date primarily through equity financing. Additional funding will be required to complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure. On March 11, 2021, the Company closed a private placement of 1,304,346 ordinary shares and accompanying warrants to purchase an aggregate of up to 652,173 ordinary shares at a combined purchase price of $4.60 per share and accompanying warrant resulting in gross proceeds of $6,000. The warrants are exercisable immediately at an exercise price of $4.60 per share and expire five and a half years On July 22 2021, the Company issued 419,673 ordinary shares upon exercise of warrants for consideration totalling $1,930 (Note 9). Based on the Company's current operating plan, the Company believes that its existing capital resources will be sufficient to fund operations for at least twelve months after the date the financial statements are issued. c. The Company effected a 3-for-1 reverse split of the Company’s ordinary shares and convertible preferred shares on July 6, 2020. All issued and outstanding ordinary shares and convertible preferred shares and related per share amounts contained in these financial statements have been retroactively adjusted to reflect this reverse share split for all periods presented. On September 3, 2020, the Company closed its initial public offering ("IPO") of 2,500,000 units at a price of $8.00 per unit. Each unit consisted of one ordinary share and one warrant to purchase one ordinary share. The ordinary shares and warrants were immediately separable from the units and were issued separately. The warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $8.80 per share. On October 5, 2020, the underwriters exercised their over-allotment option and were issued warrants to purchase 375,000 ordinary shares in return for net amount of $3. The Company received gross proceeds of approximately $20,000 (net proceeds of approximately $17.3 million after deducting underwriting discounts and commissions and other offering expenses). d. In late 2019, a novel strain of COVID-19, was reported in Wuhan, China. While initially the outbreak was largely concentrated in China, it rapidly spread across the globe, including in Israel and the United States. The extent to which COVID-19 pandemic impacts the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain the COVID-19 or treat its impact. As of December 31, 2021 and signing date on these financial statements the Company did not experience a significant impact on its operation.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES a. Basis of presentation: The financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The significant accounting policies described below have been applied consistently in relation to all the periods presented, unless otherwise stated. b. Use of estimate in preparation of financial statements: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. c. Financial statements in United States dollars: The Company’s functional currency is the U.S. dollar (“dollar” or “$”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in currencies other than dollars have been re-measured to dollars at the dates of the transactions. All transaction gains and losses from re-measurement and from translation of monetary balance sheet items denominated in currencies other than dollars are reflected in the statements of comprehensive loss as financial expenses, net. d. Cash and cash equivalents: Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. e. Restricted cash: As of December 31, 2021 and 2020, the Company’s restricted cash consisted of immaterial bank deposits that were denominated in New Israeli Shekel. Restricted deposits are presented at cost including accrued interest. These bank deposits are used as securities for the Company's credit card and rent guaranty. f. Fair Value Measurements: The carrying values of Company’s financial assets and liabilities, including cash and cash equivalents, restricted cash, other current assets, trade payables and other accounts payable approximate their fair value due to the short-term maturity of these instruments. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value in the financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: Level 1 Level 2 Level 3 As of December 31, 2019 the Company’s derivative warrant liability was classified within Level 3 of the fair value hierarchy because their fair values are estimated by utilizing valuation models and significant unobservable inputs. During 2020 the derivative warrant was classified to equity (see note 4). As of December 31, 2021, and 2020 no assets or liabilities are measured in fair value. g. Property and equipment, net: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers, software and electronic equipment 33 Furniture and office equipment 7 Leasehold improvements * *The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise. h. Research and development expenses: Research and development costs include costs of payroll and related expenses of employees, subcontractors and consultants and other costs related to the Company's operation of its planned clinical trial. Research and development expenses are charged to the statements of comprehensive loss as incurred. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources its clinical trial activities utilizing external entities such as clinical research organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical trials. Clinical trial costs are expensed as incurred. i. Income taxes: The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. ASC 740 prescribes the use of the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized. As of December 31, 2021, and 2020, the Company had a full valuation allowance on its deferred tax assets. The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax positions as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement. As of December 31, 2021 and 2020, the total gross amount of provision for unrecognized tax positions was $234 and $220, respectively (Note 6e). The Company recognizes interest and penalties, if any, related to unrecognized tax positions in tax expenses and exchange differences in financial expense. j. Concentrations of credit risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted cash. Cash and cash equivalents and restricted cash are invested in a major bank in Israel and the United States. Management believes that the banks that hold the Company’s cash, cash equivalent and restricted cash are financially sound and, accordingly, minimal credit risk exists with respect to this cash, cash equivalent and restricted cash. The Company relies, and expects to continue to rely, on a single supplier to manufacture supplies and raw materials for its clinical trial. This clinical trial could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials. k. Convertible notes: Proceeds from the sale of notes with a conversion feature are allocated to equity based on the intrinsic value of such conversion feature (if any) in accordance with ASC 470-20 “Debt with Conversion and Other Options”, with a corresponding discount on the notes recorded in liabilities which is amortized in finance expense over the term of the notes. Convertible notes with convertible features that are determined to not be beneficial are allocated entirely to liabilities. l. Derivative warrant liability Financial equity instruments that do not meet the US GAAP criteria for equity classification are classified as a liability at fair value and are adjusted to fair value at each reporting period. Changes in fair value are recognized in the Company’s statements of comprehensive loss in accordance with ASC 815, “Accounting for Derivative Financial Instruments”. m. Basic and diluted loss per share: Basic loss per share is computed by dividing the loss for the period applicable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. For the years ended December 31, 2021, 2020 and 2019, all outstanding share options, convertible notes, and warrants have been excluded from the calculation of the diluted net loss per share as all such securities are anti-dilutive for all years presented. The loss and the weighted average number of shares used in computing basic and diluted net loss per share is as follows: Year ended 2021 2020 2019 Numerator: Net loss applicable to shareholders of ordinary shares $ (7,246 ) $ (4,053 ) $ (1,279 ) Interest accrued on convertible preferred shares - - (1,130 ) Total loss attributed to ordinary shares (7,246 ) (4,053 ) (2,409 ) Denominator: Shares of ordinary share used in computing basic and diluted net loss per share 9,812,234 3,243,943 576,556 Net loss per share of ordinary share, basic and diluted $ (0.74 ) $ (1.25 ) $ (4.17 ) n. Share-based compensation: Share-based compensation to employees and consultants is accounted for in accordance with ASC 718, “Compensation - Share Compensation” (“ASC 718”), which requires estimation of the fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service period using the graded vesting method. The Company has elected to recognize forfeitures, as incurred. The fair value of share options granted was estimated using the Black Scholes model, which requires a number of assumptions, of which the most significant are the expected share price, volatility, and the expected option term. Expected volatility was calculated based on comparable public companies in the same industry. The expected share option term is calculated for share options granted using the “simplified” method. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The expected dividend yield assumption is based on the Company’s historical experience and expectation of no future dividend pay outs. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future. o. Deferred offering costs The Company capitalizes certain legal and other third-party fees that are directly related to the Company’s in-process equity financings until such financings are consummated. After the consummation of such equity financings, these costs are recorded as a reduction of the respective gross proceeds. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are written off to operating expenses. As of December 31, 2021 and 2020, there were no deferred offering costs. p. Segment Reporting The Company has one operating segment. An operating segment is defined as a component that engages in business activities whose operating results are reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources and for which discrete financial information is available. q . Leases Right of Use ("ROU") assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company elected the practical expedient of the short-term lease recognition exemption for all leases with a term shorter than 12 months r. Disclosure of recent accounting pronouncements ASC Topic 740, "Income Taxes ", was amended to simplify the accounting for income taxes to improve consistency of accounting methods and remove certain exceptions. Effective January 1, 2021, the Company adopted this income taxes amendment. The implementation of the updated guidance did not have a significant effect on the Company’s financial statements. s. Issued accounting pronouncements effective in future periods In August 2020, the FASB issued guidance that is expected to reduce complexity and improve comparability of financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. This guidance will be effective for the Company on January 1, 2022 and is not expected to have a material impact on the Company’s financial statements and disclosures.

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 3:- PREPAID EXPENSES AND OTHER CURRENT ASSETS December 31, 2021 2020 Receivables from governmental authorities $ 218 $ 53 Prepaid expenses 473 734 Other 30 20 $ 721 $ 807

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 4:- FAIR VALUE MEASUREMENTS During the year ended December 31, 2019, the Company issued warrants related to its convertible notes (refer to Note 5(b)). As of December 31, 2019, the warrants did not meet the US GAAP criteria for equity classification, and accordingly were classified as a derivative warrant liability and were measured at fair value on the issuance date and as of December 31, 2019, as well as through the date of consummation of the IPO, with changes in fair value recognized as financial expenses in the statements of comprehensive loss. On September 3, 2020, upon consummation of the IPO, the exercise price of the warrants and the number of shares to be issued upon exercise of the warrants were fixed (refer to Note 5(b)), such that it then met the criteria for equity classification of the warrants under US GAAP. Accordingly, the derivative warrant liability was classified to equity as of such date. A summary of significant unobservable inputs (Level 3 inputs) used in measuring as follows: September 3, December 31 2020 2019 Exercise price $6.72-$8.80 $2.55-$4.74 Expected volatility 72.29% 72.29% Risk free rate 0.22% 1.5-1.67% Expected life (years) 3.98-5 4.65-5 Dividend yield - - The following table presents changes in the fair value of the derivative warrant liability recorded in respect of the warrants: Balance as of December 31, 2018 $ - Issuance of warrants in connection with convertible notes (Note 5 (b)) 445 Changes in fair value 2 Balance as of December 31, 2019 $ 447 Changes in fair value 1,105 Equity classification of a derivative warrant liability (1,552 ) $ -

CONVERTIBLE NOTES

CONVERTIBLE NOTES	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
CONVERTIBLE NOTES	NOTE 5:- CONVERTIBLE NOTES a. From 2014 until 2019, the Company issued convertible notes in the total principal amount of $4,417 to existing shareholders. The Company recorded interest expense amounting to $271 and $379 for the years ended December 31, 2020 and 2019, respectively. Concurrent with the closing of the IPO, all of the Company’s convertible notes (inclusive of accrued interest on all outstanding notes) were converted into 2,415,022 units (consisting of one ordinary share and one warrant to purchase one ordinary share). b. In August and December 2019, the Company issued 14.2 units of convertible notes (the “2019 Convertible Notes”) and warrants. Each unit consisted of one convertible note and one warrant. In consideration for the units issued the Company received a total amount of $1,420 (representing a consideration of $100 per unit), after giving effect to a 10% discount. On September 3, 2020, upon consummation of the IPO, the outstanding balance of the 2019 Convertible Notes was converted into 312,170 units, each consisting of one ordinary share and one warrant to purchase one ordinary share, exercisable immediately, at an exercise price of $8.80 and with an expiry date of 5 years from the IPO closing date (refer to note 1(c)). Additionally, on the IPO consummation date, the amount and exercise price of the warrants originally granted in August and December 2019, was fixed at 297,589 warrants and at an exercise price of $6.72, each exercisable into a single unit (refer to Note 1(c)), consisting of one ordinary share and one warrant to purchase one ordinary shares, exercisable through September 3, 2025, at an exercise price of $8.80. Accordingly, since the warrants met the criteria of equity classification, the respective derivative warrant liability, was classified in equity (refer to note 4). c. On December 9, 2019, in connection with the 2019 Convertible Notes, the Company issued to the placement agent in the offering described above warrants (the “Agents' Warrants”) to purchase an aggregate of 55,785 ordinary shares or units (refer to Note 1(d)), at an exercise price of $6.72 per unit. Each unit consists of one ordinary share and one warrant to purchase one ordinary share, exercisable through September 3, 2025, at an exercise price of $8.80. The Agents' Warrants expire on December 8, 2024. As a result of the issuance of the Agents' Warrants, the Company recorded a discount on the convertible note, which was amortized as financial expense amounting to $65 for the year ended December 31, 2020.

TAXES ON INCOME

TAXES ON INCOME	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
TAXES ON INCOME	NOTE 6:- TAXES ON INCOME a. Tax rates applicable to the Company: Taxable income of the Company is subject to the Israeli Corporate tax rate which was 23% for the years ended December 31, 2021,2020 and 2019. b. Net operating loss carry forward: As of December 31, 2021, and 2020, the Company had net operating loss carry forwards for Israeli income tax purposes of approximately $19,261 and $15,114, respectively. Net operating loss carry forwards in Israel may be carried forward indefinitely and offset against future taxable income. c. As of December 31, 2021, the Company had final tax assessments for tax years prior to and including the tax year ended December 31, 2015. d. Deferred income taxes: Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows: December 31, 2021 2020 Deferred tax assets: Net operating loss carry forward $ 4,434 $ 3,476 Deferred tax asset before valuation allowance 4,434 3,476 Valuation allowance (4,434 ) (3,476 ) Net deferred tax asset $ - $ - In assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences are deductible and net operating losses are utilized. Based on consideration of these factors, the Company recorded a full valuation allowance on December 31, 2021 and 2020. e. Reconciliation of theoretical tax expenses to actual expenses The primary difference between the statutory tax rate of the Company and the effective rate results virtually from the changes in valuation allowance in respect of carry forward tax losses, share based compensation expenses and research and development expenses due to the uncertainty of the realization of such tax benefits. f. Uncertain tax positions: A reconciliation of the opening and closing amounts of total unrecognized tax benefits is as follows: December 31, December 31, December 31, 2021 2020 2019 Opening balance 220 - - Tax positions taken in the current year - 217 - Interest 6 3 - Exchange difference 8 - - Closing balance $ 234 $ 220 $ - The balance of total unrecognized tax position as of December 31, 2021 is $234 which, if recognized, would affect the effective tax rate in the Company's statements of comprehensive loss. The Company recognizes interest and penalties, if any, related to unrecognized tax positions in tax expenses and exchange differences in financial expense. The accrued interest and exchange difference related to uncertain tax positions and the expenses recognized during the year ended December 31, 2021, are $9 and $8.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7:- COMMITMENTS AND CONTINGENCIES a. During the years ended December 31, 2020 and 2019, the Company was party to a lease agreement with a related party for an annual fee of $33. As of December 31, 2020, the lease agreement with the related party was terminated. On December 10, 2020, the Company entered into a new rental agreement with an un-related party for a period of twelve months starting on January 1, 2021, with an extension option for an additional twelve months, for an annual rental fee of $20. As of December 31, 2021 the agreement was terminated. On July 26, 2021 the Company engaged in a new rental agreement with an un-related party for a period of twelve months starting on August 15, 2021 with an extension option for an additional twelve months subject to the Company's prior notice. The annual rent fees are $75. The Company gave the lessor a bank guaranty of $16, as collateral and the bank holds this amount restricted cash. On November 23, 2020, the Company entered into an employment agreement with Rita Kenan under which Mrs. Kenan serves as the VP Operations commencing January 1, 2021. Under the terms of the agreement, the Company paid Mrs. Keenan a bonus, in the amount of $45 in 2021. c. On November 13, 2020 and December 3, 2020, the Company entered into a Master Clinical Research Organization Agreement (the “First Agreement”) and a Master Clinical Trial Agreement (the “Second Agreement”) with Lotus Clinical Research ("Lotus") as the Company's clinical research organization. According to the agreements Lotus will serve as the clinical research organization for the Company's planned Phase 3 trials of PRF-110, which are expected to take place in 2022. Under the first agreement, the Company is obligated to pay an accumulated amount of approximately $2,907 (excluding pass-through costs) upon milestone completions and under the second agreement an accumulated amount of approximately $7,107 (excluding advertising budget) upon actual number of evaluable subjects. Under the First Agreement, a non-refundable payment of $581 was made on December 28, 2020. In Addition, during 2021 payments in a total amount of $581 were made according to milestones set in the agreement. Under the Second Agreement, a non-refundable deposit (the “Second Agreement Deposit”) of $710 was made on January 12, 2021. As of December 31, 2021 and 2020, the Company accounted for these amounts of net $1,728 and $1,294 as prepaid clinical trial expense and deferred clinical trial costs after recognition of $145 clinical trials expenses in 2021 .

TEMPORARY EQUITY

TEMPORARY EQUITY	12 Months Ended
	Dec. 31, 2021
Temporary Equity Disclosure [Abstract]
TEMPORARY EQUITY	NOTE 8:- TEMPORARY EQUITY Convertible Preferred Shares Convertible preferred shares consisted of the following: Convertible Preferred Shares - Series A Shares Shares Carrying Liquidation As of December 31, 2019 18,300,000 2,954,267 $ 6,621 $ 15,250 The preferred shares conferred upon their holders all rights accruing to holders of ordinary shares in the Company, and, in addition, the rights, preferences and privileges granted to the preferred shares as follows. On September 3, 2020, upon consummation of the IPO, all of the Company’s outstanding convertible preferred shares were converted into 2,954,267 ordinary shares.

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
SHAREHOLDERS' EQUITY	NOTE 9:- SHAREHOLDERS’ EQUITY Ordinary shares The ordinary shares confer upon their holders the right to participate and vote in general shareholder meetings of the Company and to share in the distribution of dividends, if any, declared by the Company, and rights to receive a distribution of assets upon liquidation. Shares developments a. On July 6, 2020, pursuant to the Company’s shareholders approval, the Company effected a 3-for-1 reverse split of the Company’s ordinary shares and convertible preferred shares. b. In addition, on the IPO closing date, the Company granted to the underwriters of the IPO warrants to purchase 125,000 ordinary shares, which equals five percent (5%) of the total number of units sold in the IPO, excluding the over-allotment option, at an exercise price $10.00 per share. The warrants (the “Underwriters’ Warrants”) contain a cashless exercise feature. The Underwriters’ Warrants are exercisable for ordinary shares on a cash or cashless basis at an exercise price of $10.00 per ordinary share which price reflects 125% of the public offering price of the units issued in the offering. The Underwriters’ Warrants are exercisable following twelve (12) months after the effective date of the registration statement relating to the IPO and expire five (5) years after such effective date. The Underwriters’ Warrants are non-transferable. As part of the IPO, the Company granted the IPO underwriters an over-allotment to purchase up to 375,000 additional warrants at the public offering price of $0.01, less the underwriting discounts and commissions. On October 5, 2020 the underwriters exercised their over-allotment option and were issued warrants to purchase 375,000 ordinary shares in return for net amount of $3. The warrants are exercisable through September 3, 2025, at an exercise price of $8.80. c. On March 11, 2021, the Company issued to certain institutional investors (the “Purchasers”) 1,304,346 ordinary shares and warrants to purchase up to an aggregate of 652,173 ordinary shares at a combined purchase price of $4.60 per ordinary share and accompanying warrant in a Private Investment in Public Equity ("Private placement") pursuant to a securities purchase agreement. The private placement resulted in gross proceeds of approximately $6,000. The Company received net amount of $5,554 less issuance costs. On July 22, 2021, as a result of an exercise of warrants to purchase 419,673 shares held by one of the Purchasers, the Company received gross proceeds of $1,930. In connection with the private placement, the Company also entered into a Registration Rights Agreement, dated as of March 8, 2021, with the Purchasers (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, the Company filed a registration statement (the “Registration Statement”), with the SEC to register the resale of the ordinary shares and the ordinary shares issuable upon exercise of the warrants. The Registration Statement was declared effective on April 9, 2021. The Company paid the placement agents of the private placement a cash placement fee equal to $390 and an expense reimbursement of $40. The Company also issued to the placement agents warrants to purchase 52,173 ordinary shares, at an exercise price of $5.06 per ordinary share and a term expiring on March 10, 2026. The Company paid a total of approximately $500 in placement agent fees and other expenses. Warrants and warrants units The following table summarizes the warrants and warrants units outstanding as of December 31, 2021: Type ISSUANCE DATE NUMBER OF WARRANTS EXERCISE PRICE EXERCISABLE THROUGH August 2019 warrants (note 5b) August 22, 2019 205,268 $6.72 (*) August 22, 2024 December 2019 warrants (note 5b) December 9, 2019 92,321 $6.72 (*) December 8, 2024 Warrants to 2019 Convertible Notes placement agent (note 5c) December 9, 2019 55,785 $6.72 (*) December 8, 2024 Warrants to underwriters (note 9) September 3, 2020 125,000 $10.00 September 1, 2025 Warrants to underwriters (note 9) October 5, 2020 375,000 $8.80 September 3, 2025 IPO warrants (note 1d, note 5b) September 3, 2020 2,812,170 $8.80 September 3, 2025 PIPE warrants (note 1c) March 11, 2021 232,500 $4.60 September 10, 2026 Warrants to PIPE placement agent (note 1c) March 11,2021 52,173 $5.06 March 8, 2026 Total 3,950,217 (*) Each warrant is exercisable into a unit consisting of one share and one warrant Share-based compensation a. The 2008 Plan On August 7, 2008, the Board of Directors approved the adoption of the 2008 Share Option Plan (the “2008 Plan”). As of December 31, 2021, and 2020, 153,882 share options were outstanding and no share options were available for future grant under the 2008 Plan. Each share option granted is exercisable at such times and terms and conditions as the Board of Directors may specify in the applicable share option agreement, provided that no share option will be granted with a term in excess of 10 years. The intrinsic value of share options outstanding and exercisable as of December 31, 2021, 2020 and 2019 was $168, $651 and $275, respectively. Number of options Weighted average exercise price Weighted average remaining contractual life Options outstanding as of December 31, 2019 153,882 $ 0.24 4.25 Options granted in 2020 Options outstanding as of December 31, 2020 153,882 $ 0.24 3.25 Options granted in 2021 Options outstanding as of December 31, 2021 153,882 $ 0.24 2.25 Options exercisable as of December 31, 2021 153,882 $ 0.24 2.25 b. The 2019 Plan On July 2, 2019, the Board of Directors approved the adoption of the 2019 Share Option Plan (the “2019 Plan”). Under the 2019 Plan, the Company may grant its officers, directors, employees and consultants share options of the Company. Each share option granted shall be exercisable at such times and terms and conditions as the Board of Directors may specify in the applicable share option agreement, provided that no share option will be granted with a term in excess of 10 years. Upon the adoption of the 2019 Plan, the Company reserved for issuance 971,476 ordinary shares. As of December 31, 2021, share options to purchase 971,476 ordinary shares were outstanding (as of December 31, 2020, share options to purchase 219,456 ordinary shares were outstanding). On February 23, 2021, the shareholders of the Company approved the grant of options to purchase an aggregate of 300,000 ordinary shares to three current board members, the Chairman of the board of directors and to the Chief Technology Officer (who is also a director). Each was granted with options to purchase 60,000 ordinary shares of the Company. The options are exercisable to acquire one Ordinary share of the Company at an exercise price of $4.50 per share. The options vest on a quarterly basis over thirty-six months, so that 1/12 of the options shall vest on the last day of each three-month period, provided that on such date each of the serving directors and Chief Technology Officer, shall serve in such capacity. The options will expire after ten years from their grant date. In January through May 2021 the Company granted an aggregate of 452,020 options to employees. The options are exercisable at exercise prices ranging from $3.01 to $5.74 per share. The options vest over a four year period, 4/16 of the options shall vest following the lapse of a period of twelve months commencing at the date of grant. The remaining 12/16 of the options shall vest on quarterly basis, so that 1/12 of the options shall vest on the expiry of each quarter, provided that on such date each of the employees shall continue to provide the services as an employee of the Company. The options will expire after ten years from their grant date. The following table summarizes information about options granted to employees: Year ended December 31, 2021 Year ended December 31, 2020 Year ended December 31, 2019 Number of options Weighted average Exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at the beginning of the year 219,456 2.62 219,456 2.62 - - Granted 752,020 5.07 - - 219,456 2.62 Forfeited - - - - - - Exercised - - - - - - Outstanding at the end of the year 971,476 4.51 219,456 2.62 219,456 2.62 Exercisable at the end of the year 361,280 3.58 200,269 2.55 156,386 2.77 c. The following table sets forth the assumptions that were used in determining the fair value of options granted to employees in 2019 plan for the years ended on December 31, 2021, 2020 and 2019: Year ended December 31 2021 2020 2019 Expected life 5.86-6.11 - 5.75-10 Risk-free interest rates 0.52%-1.13 % - 1.43%-2.13 % Volatility 69.67%-78.99 % - 82.29%-85.56 % Dividend yield - - - Exercise price $ 3.013-5.738 - $ 0.24-3.339 The Company recognized $713 and $18 during the years ended December 31, 2021 and 2020, respectively, as share-based compensation expense which was included in general and administrative expenses, and $99 and $18 during the years ended December 31, 2021 and 2020, respectively, as share-based compensation expense which was included in research and development expenses. The following table summarizes information about share options outstanding and exercisable in 2019 plan to employees and directors during the years ended December 31, 2020 were as follows: Number of options Weighted average exercise price Weighted average remaining contractual life Options outstanding as of December 31, 2020 219,456 $ 2.62 8.56 Options granted in 2021 752,020 $ 5.06 9.05 Options outstanding as of December 31, 2021 971,746 $ 4.51 8.72 Options exercisable as of December 31, 2021 361,280 $ 3.58 8.14 The intrinsic value of share options outstanding as of December 31, 2021 and 2020 was $224 and $407, respectively. The intrinsic value of share options exercisable as of December 31, 2021 and 2020 was $224 and $385, respectively. d. In August 2020, the Company entered into an IR/PR service agreement (the “Service Agreement”) with Crescendo Communications, LLC (“Crescendo”), for a period of two years, commencing immediately after the IPO closing date, and in consideration for 152,110 restricted Company's ordinary shares, reflecting 3.75% of the Company's' share capital fully diluted Pre-IPO. On August 23, 2020, the Company's Board of Directors approved the Service Agreement with Crescendo and the grant of the abovesaid ordinary shares. The Company recognized $412 and $137 during the year ended December 31, 2021 and 2020 as share-based compensation expense related to the shares. As of December 31, 2021, the foregoing shares have not been formally issued.

SELECTED STATEMENTS OF OPERATIO

SELECTED STATEMENTS OF OPERATIONS DATA	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block Supplement [Abstract]
SELECTED STATEMENTS OF OPERATIONS DATA	NOTE 10:- SELECTED STATEMENTS OF OPERATIONS DATA a. Research and development expenses: Year ended December 31, 2021 2020 2019 Subcontractors and consultants $ 1,654 $ 217 $ 21 Payroll and related expenses 719 90 59 Share-based compensation expense 99 18 14 Clinical trials expenses 357 - - Other expenses 31 29 42 $ 2,860 $ 354 $ 136 b. General and administrative expenses: Year ended December 31, 2021 2020 2019 Professional services $ 1,697 $ 727 $ 342 Payroll and related expenses 688 154 60 D&O insurance 935 360 - Rent and office maintenance 210 37 33 Share-based compensation expense 713 20 75 Other expenses 105 19 43 $ 4,348 $ 1,317 $ 553 c. Financial expenses, net: Year ended December 31, 2021 2020 2019 Interest expense and amortization of discount on convertible notes $ - $ 987 $ 541 Issuance expenses - 65 47 Bank fees 10 3 2 Change in fair value of derivative warrant liability - 1,105 2 Exchange rate differences 22 2 (2 ) Total financial expenses, net $ 32 $ 2,162 $ 590

RELATED PARTIES BALANCES AND TR

RELATED PARTIES BALANCES AND TRANSACTIONS	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTIES BALANCES AND TRANSACTIONS	NOTE 11:- RELATED PARTIES BALANCES AND TRANSACTIONS a. During the year ended 2019 the Company issued convertible notes in the amount of $95, to existing shareholders. As described under Note 5 above, the notes bore interest at an annual interest rate of 8%, compounded on the basis of a 365-day year and were convertible into convertible preferred shares of the Company. b. Starting in January 2014, the Company sub-leased office space and received management services from Zori Medica 2010 Ltd., a private company affiliated with Medica Venture Partners, the controlling shareholder of the Company. The Company was subject to an annual rental fee of $33 for the office space and $20 as a quarterly management fee. The management services continued until the end of March 2018. The sublease ceased as of August 2019, and from then until December 31, 2020 the Company was provided with an office space at no cost by Medica Venture Partners. For the years ended December 31, 2020 and 2019, the Company recorded an amount of $33 and $25, respectively, as a lease expense and a corresponding increase in additional paid-in capital, representing a contribution from its controlling shareholder. As of December 31, 2020, the lease agreement with the related party was terminated. c. On January 26, 2020, the Company’s Board of Directors approved a one-time immediate payment of $150 and a payment of $37.5 on a quarterly basis (for such time as the service engagement continues) to the Chairman of the Board of Directors contingent upon shareholder approval which was granted on July 6, 2020 and successful completion of Company’s IPO which closed on September 3, 2020. d. On February 23, 2021, the shareholders of the Company approved the grant of options to purchase an aggregate of 300,000 ordinary shares to three board members, the Chairman of the board of directors and to its Chief Technology Officer (who also serves as a director). Balances with related parties: 2021 2020 Employees accrued salaries $ 356 $ 79 Directors accrued expenses $ 82 $ 35 $ 438 $ 114 Transactions with related parties: 2021 2020 2019 Amounts charged to: Research and development expenses $ 151 $ - $ - General and administrative expenses 2,155 370 210 Interest expense on convertible notes $ - $ 251 $ 351

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of presentation	a. Basis of presentation: The financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The significant accounting policies described below have been applied consistently in relation to all the periods presented, unless otherwise stated.
Use of estimate in preparation of financial statements	b. Use of estimate in preparation of financial statements: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.
Financial statements in United States dollars	c. Financial statements in United States dollars: The Company’s functional currency is the U.S. dollar (“dollar” or “$”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in currencies other than dollars have been re-measured to dollars at the dates of the transactions. All transaction gains and losses from re-measurement and from translation of monetary balance sheet items denominated in currencies other than dollars are reflected in the statements of comprehensive loss as financial expenses, net.
Cash and cash equivalents	d. Cash and cash equivalents: Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.
Restricted cash	e. Restricted cash: As of December 31, 2021 and 2020, the Company’s restricted cash consisted of immaterial bank deposits that were denominated in New Israeli Shekel. Restricted deposits are presented at cost including accrued interest. These bank deposits are used as securities for the Company's credit card and rent guaranty.
Fair Value Measurements	f. Fair Value Measurements: The carrying values of Company’s financial assets and liabilities, including cash and cash equivalents, restricted cash, other current assets, trade payables and other accounts payable approximate their fair value due to the short-term maturity of these instruments. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value in the financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: Level 1 Level 2 Level 3 As of December 31, 2019 the Company’s derivative warrant liability was classified within Level 3 of the fair value hierarchy because their fair values are estimated by utilizing valuation models and significant unobservable inputs. During 2020 the derivative warrant was classified to equity (see note 4). As of December 31, 2021, and 2020 no assets or liabilities are measured in fair value.
Property and equipment, net	g. Property and equipment, net: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers, software and electronic equipment 33 Furniture and office equipment 7 Leasehold improvements * *The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise.
Research and development expenses	h. Research and development expenses: Research and development costs include costs of payroll and related expenses of employees, subcontractors and consultants and other costs related to the Company's operation of its planned clinical trial. Research and development expenses are charged to the statements of comprehensive loss as incurred. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources its clinical trial activities utilizing external entities such as clinical research organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical trials. Clinical trial costs are expensed as incurred.
Income taxes	i. Income taxes: The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. ASC 740 prescribes the use of the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized. As of December 31, 2021, and 2020, the Company had a full valuation allowance on its deferred tax assets. The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax positions as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement. As of December 31, 2021 and 2020, the total gross amount of provision for unrecognized tax positions was $234 and $220, respectively (Note 6e). The Company recognizes interest and penalties, if any, related to unrecognized tax positions in tax expenses and exchange differences in financial expense.
Concentrations of credit risk	j. Concentrations of credit risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted cash. Cash and cash equivalents and restricted cash are invested in a major bank in Israel and the United States. Management believes that the banks that hold the Company’s cash, cash equivalent and restricted cash are financially sound and, accordingly, minimal credit risk exists with respect to this cash, cash equivalent and restricted cash. The Company relies, and expects to continue to rely, on a single supplier to manufacture supplies and raw materials for its clinical trial. This clinical trial could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.
Convertible notes	k. Convertible notes: Proceeds from the sale of notes with a conversion feature are allocated to equity based on the intrinsic value of such conversion feature (if any) in accordance with ASC 470-20 “Debt with Conversion and Other Options”, with a corresponding discount on the notes recorded in liabilities which is amortized in finance expense over the term of the notes. Convertible notes with convertible features that are determined to not be beneficial are allocated entirely to liabilities.
Derivative warrant liability	l. Derivative warrant liability Financial equity instruments that do not meet the US GAAP criteria for equity classification are classified as a liability at fair value and are adjusted to fair value at each reporting period. Changes in fair value are recognized in the Company’s statements of comprehensive loss in accordance with ASC 815, “Accounting for Derivative Financial Instruments”.
Basic and diluted loss per share	m. Basic and diluted loss per share: Basic loss per share is computed by dividing the loss for the period applicable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. For the years ended December 31, 2021, 2020 and 2019, all outstanding share options, convertible notes, and warrants have been excluded from the calculation of the diluted net loss per share as all such securities are anti-dilutive for all years presented. The loss and the weighted average number of shares used in computing basic and diluted net loss per share is as follows: Year ended 2021 2020 2019 Numerator: Net loss applicable to shareholders of ordinary shares $ (7,246 ) $ (4,053 ) $ (1,279 ) Interest accrued on convertible preferred shares - - (1,130 ) Total loss attributed to ordinary shares (7,246 ) (4,053 ) (2,409 ) Denominator: Shares of ordinary share used in computing basic and diluted net loss per share 9,812,234 3,243,943 576,556 Net loss per share of ordinary share, basic and diluted $ (0.74 ) $ (1.25 ) $ (4.17 )
Share-based compensation	n. Share-based compensation: Share-based compensation to employees and consultants is accounted for in accordance with ASC 718, “Compensation - Share Compensation” (“ASC 718”), which requires estimation of the fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service period using the graded vesting method. The Company has elected to recognize forfeitures, as incurred. The fair value of share options granted was estimated using the Black Scholes model, which requires a number of assumptions, of which the most significant are the expected share price, volatility, and the expected option term. Expected volatility was calculated based on comparable public companies in the same industry. The expected share option term is calculated for share options granted using the “simplified” method. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The expected dividend yield assumption is based on the Company’s historical experience and expectation of no future dividend pay outs. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.
Deferred offering costs	o. Deferred offering costs The Company capitalizes certain legal and other third-party fees that are directly related to the Company’s in-process equity financings until such financings are consummated. After the consummation of such equity financings, these costs are recorded as a reduction of the respective gross proceeds. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are written off to operating expenses. As of December 31, 2021 and 2020, there were no deferred offering costs.
Segment Reporting	p. Segment Reporting The Company has one operating segment. An operating segment is defined as a component that engages in business activities whose operating results are reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources and for which discrete financial information is available.
Leases	q . Leases Right of Use ("ROU") assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company elected the practical expedient of the short-term lease recognition exemption for all leases with a term shorter than 12 months
Disclosure of recent accounting pronouncements	r. Disclosure of recent accounting pronouncements ASC Topic 740, "Income Taxes ", was amended to simplify the accounting for income taxes to improve consistency of accounting methods and remove certain exceptions. Effective January 1, 2021, the Company adopted this income taxes amendment. The implementation of the updated guidance did not have a significant effect on the Company’s financial statements.
Issued accounting pronouncements effective in future periods	s. Issued accounting pronouncements effective in future periods In August 2020, the FASB issued guidance that is expected to reduce complexity and improve comparability of financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. This guidance will be effective for the Company on January 1, 2022 and is not expected to have a material impact on the Company’s financial statements and disclosures.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule Of Depreciation Rates For Property And Equipment	% Computers, software and electronic equipment 33 Furniture and office equipment 7 Leasehold improvements * *The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise.
Schedule of Computation of Basic and Diluted Losses Per Share	Year ended 2021 2020 2019 Numerator: Net loss applicable to shareholders of ordinary shares $ (7,246 ) $ (4,053 ) $ (1,279 ) Interest accrued on convertible preferred shares - - (1,130 ) Total loss attributed to ordinary shares (7,246 ) (4,053 ) (2,409 ) Denominator: Shares of ordinary share used in computing basic and diluted net loss per share 9,812,234 3,243,943 576,556 Net loss per share of ordinary share, basic and diluted $ (0.74 ) $ (1.25 ) $ (4.17 )

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	December 31, 2021 2020 Receivables from governmental authorities $ 218 $ 53 Prepaid expenses 473 734 Other 30 20 $ 721 $ 807

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of significant unobservable inputs (Level 3 inputs) used in measuring the warrants	September 3, December 31 2020 2019 Exercise price $6.72-$8.80 $2.55-$4.74 Expected volatility 72.29% 72.29% Risk free rate 0.22% 1.5-1.67% Expected life (years) 3.98-5 4.65-5 Dividend yield - -
Schedule of Changes in the Fair Value of Derivative Warrant Liability	Balance as of December 31, 2018 $ - Issuance of warrants in connection with convertible notes (Note 5 (b)) 445 Changes in fair value 2 Balance as of December 31, 2019 $ 447 Changes in fair value 1,105 Equity classification of a derivative warrant liability (1,552 ) $ -

TAXES ON INCOME (Tables)

TAXES ON INCOME (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Deferred Income Taxes	December 31, 2021 2020 Deferred tax assets: Net operating loss carry forward $ 4,434 $ 3,476 Deferred tax asset before valuation allowance 4,434 3,476 Valuation allowance (4,434 ) (3,476 ) Net deferred tax asset $ - $ -
Schedule of Unrecognized Tax Benefits	December 31, December 31, December 31, 2021 2020 2019 Opening balance 220 - - Tax positions taken in the current year - 217 - Interest 6 3 - Exchange difference 8 - - Closing balance $ 234 $ 220 $ -

TEMPORARY EQUITY (Tables)

TEMPORARY EQUITY (Tables)	12 Months Ended
	Dec. 31, 2021
Temporary Equity Disclosure [Abstract]
Schedule of Convertible Preferred Shares	Convertible preferred shares consisted of the following: Convertible Preferred Shares - Series A Shares Shares Carrying Liquidation As of December 31, 2019 18,300,000 2,954,267 $ 6,621 $ 15,250

SHAREHOLDERS' EQUITY (Tables)

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of warrants and warrants units outstanding	Type ISSUANCE DATE NUMBER OF WARRANTS EXERCISE PRICE EXERCISABLE THROUGH August 2019 warrants (note 5b) August 22, 2019 205,268 $6.72 (*) August 22, 2024 December 2019 warrants (note 5b) December 9, 2019 92,321 $6.72 (*) December 8, 2024 Warrants to 2019 Convertible Notes placement agent (note 5c) December 9, 2019 55,785 $6.72 (*) December 8, 2024 Warrants to underwriters (note 9) September 3, 2020 125,000 $10.00 September 1, 2025 Warrants to underwriters (note 9) October 5, 2020 375,000 $8.80 September 3, 2025 IPO warrants (note 1d, note 5b) September 3, 2020 2,812,170 $8.80 September 3, 2025 PIPE warrants (note 1c) March 11, 2021 232,500 $4.60 September 10, 2026 Warrants to PIPE placement agent (note 1c) March 11,2021 52,173 $5.06 March 8, 2026 Total 3,950,217 (*) Each warrant is exercisable into a unit consisting of one share and one warrant
Schedule of options granted to employees	The following table summarizes information about options granted to employees: Year ended December 31, 2021 Year ended December 31, 2020 Year ended December 31, 2019 Number of options Weighted average Exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at the beginning of the year 219,456 2.62 219,456 2.62 - - Granted 752,020 5.07 - - 219,456 2.62 Forfeited - - - - - - Exercised - - - - - - Outstanding at the end of the year 971,476 4.51 219,456 2.62 219,456 2.62 Exercisable at the end of the year 361,280 3.58 200,269 2.55 156,386 2.77
Schedule of Black-Scholes to estimate fair value	Year ended December 31 2021 2020 2019 Expected life 5.86-6.11 - 5.75-10 Risk-free interest rates 0.52%-1.13 % - 1.43%-2.13 % Volatility 69.67%-78.99 % - 82.29%-85.56 % Dividend yield - - - Exercise price $ 3.013-5.738 - $ 0.24-3.339
Schedule of share options outstanding and exercisable to employees and directors	Number of options Weighted average exercise price Weighted average remaining contractual life Options outstanding as of December 31, 2020 219,456 $ 2.62 8.56 Options granted in 2021 752,020 $ 5.06 9.05 Options outstanding as of December 31, 2021 971,746 $ 4.51 8.72 Options exercisable as of December 31, 2021 361,280 $ 3.58 8.14
2008 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of share options outstanding and exercisable to employees and directors	Number of options Weighted average exercise price Weighted average remaining contractual life Options outstanding as of December 31, 2019 153,882 $ 0.24 4.25 Options granted in 2020 Options outstanding as of December 31, 2020 153,882 $ 0.24 3.25 Options granted in 2021 Options outstanding as of December 31, 2021 153,882 $ 0.24 2.25 Options exercisable as of December 31, 2021 153,882 $ 0.24 2.25

SELECTED STATEMENTS OF OPERAT_2

SELECTED STATEMENTS OF OPERATIONS DATA (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block Supplement [Abstract]
Schedule of Research and Development Expenses	Year ended December 31, 2021 2020 2019 Subcontractors and consultants $ 1,654 $ 217 $ 21 Payroll and related expenses 719 90 59 Share-based compensation expense 99 18 14 Clinical trials expenses 357 - - Other expenses 31 29 42 $ 2,860 $ 354 $ 136
Schedule Of General And Administrative Expenses	Year ended December 31, 2021 2020 2019 Professional services $ 1,697 $ 727 $ 342 Payroll and related expenses 688 154 60 D&O insurance 935 360 - Rent and office maintenance 210 37 33 Share-based compensation expense 713 20 75 Other expenses 105 19 43 $ 4,348 $ 1,317 $ 553
Schedule Of Financial Expenses Net	Year ended December 31, 2021 2020 2019 Interest expense and amortization of discount on convertible notes $ - $ 987 $ 541 Issuance expenses - 65 47 Bank fees 10 3 2 Change in fair value of derivative warrant liability - 1,105 2 Exchange rate differences 22 2 (2 ) Total financial expenses, net $ 32 $ 2,162 $ 590

RELATED PARTIES BALANCES AND _2

RELATED PARTIES BALANCES AND TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Schedule of Balances and Transactions with related parties	Balances with related parties: 2021 2020 Employees accrued salaries $ 356 $ 79 Directors accrued expenses $ 82 $ 35 $ 438 $ 114 Transactions with related parties: 2021 2020 2019 Amounts charged to: Research and development expenses $ 151 $ - $ - General and administrative expenses 2,155 370 210 Interest expense on convertible notes $ - $ 251 $ 351

GENERAL (Details)

GENERAL (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 11, 2021	Oct. 05, 2020	Sep. 03, 2020	Jul. 06, 2020	Jul. 22, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Subsidiary, Sale of Stock [Line Items]
Comprehensive loss						$ 7,246	$ 4,053	$ 1,279
Accumulated deficit						$ 23,727	$ 16,481
Reverse split				3-for-1
Warrants expired	5 years 6 months
Warrants issue to purchase ordinary shares	1,304,346				419,673	3,950,217
Proceeds from Issuance of Private Placement	$ 5,554				$ 1,930
Private placement fee						$ 390
Reimbursement Expense						$ 40
Warrants exercise price	$ 4.60					$ 5.06		$ 100
Ordinary shares warrants purchase	652,173				419,673	52,173
Exercise Of Warrants Total					$ 1,930
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Shares, issued			2,500,000
Shares issued, price per share (in Dollars per share)			$ 8
Gross proceeds (in Dollars)			$ 20,000
Net proceeds (in Dollars)			$ 17,300
Warrants expired			5 years
Exercise price (in Dollars per share)			$ 8.80
Warrants exercise price			$ 8.80
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Shares, issued	1,304,346
Combined purchase price	$ 4.60					$ 4.60
Proceeds from Issuance of Private Placement	$ 6,000
Ordinary shares warrants purchase						652,173
Over-Allotment Option [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants issue to purchase ordinary shares		375,000
Proceeds from Issuance of Private Placement		$ 3

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Unrecognized tax	$ 234	$ 220	$ 0	$ 0

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)	12 Months Ended
	Dec. 31, 2021
Computers, software and electronic equipment [Member]
Property, Plant and Equipment [Line Items]
Annual depreciation rate	33.00%
Furniture, office equipment and leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Annual depreciation rate	7.00%
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Annual depreciation rate

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Computation of Basic and Diluted Losses Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Numerator
Net loss applicable to shareholders of ordinary shares		$ (7,246)	$ (4,053)	$ (1,279)
Interest accrued on convertible preferred shares		0	0	(1,130)
Total loss attributed to ordinary shares		$ (7,246)	$ (4,053)	$ (2,409)
Denominator:
Shares of ordinary share used in computing basic and diluted net loss per share	[1]	9,812,234	3,243,943	576,556
Net loss per share of ordinary share, basic and diluted (in Dollars per share)	[1]	$ (0.74)	$ (1.25)	$ (4.17)
[1]	Share and per share data is presented on a retroactive basis to reflect the reverse share split, refer to note 1(c).

PREPAID EXPENSES AND OTHER CU_3

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Schedule of Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Receivables from governmental authorities	$ 218	$ 53
Prepaid expenses	473	734
Other	30	20
Total prepaid expenses and other current assets	$ 721	$ 807

FAIR VALUE MEASUREMENTS (Schedu

FAIR VALUE MEASUREMENTS (Schedule of significant unobservable inputs (Level 3 inputs) used in measuring the warrants) (Details) - Level 3 inputs [Member] - $ / shares	8 Months Ended	12 Months Ended
	Sep. 03, 2020	Dec. 31, 2019
Defined Benefit Plan, Plan Assets, Level 3 Reconciliation [Line Items]
Expected volatility	72.29%	72.29%
Dividend yield	0.00%	0.00%
Minimum [Member]
Defined Benefit Plan, Plan Assets, Level 3 Reconciliation [Line Items]
Exercise price (in Dollars per share)	$ 6.72	$ 2.55
Risk free rate	0.22%	1.50%
Expected life (years)	3 years 11 months 23 days	4 years 7 months 24 days
Maximum [Member]
Defined Benefit Plan, Plan Assets, Level 3 Reconciliation [Line Items]
Exercise price (in Dollars per share)	$ 8.80	$ 4.74
Risk free rate		1.67%
Expected life (years)	5 years	5 years

FAIR VALUE MEASUREMENTS (Sche_2

FAIR VALUE MEASUREMENTS (Schedule of Changes in the Fair Value of the Derivative Warrant Liability) (Details) - USD ($) $ in Thousands	8 Months Ended	12 Months Ended
	Sep. 03, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Balance as of Beginning	$ 447	$ 0
Issuance of warrants in connection with convertible notes		445
Changes in fair value	1,105	2
Equity classification of a derivative warrant liability	(1,552)
Balance as of Ending	$ 0	$ 447

CONVERTIBLE NOTES (Details)

CONVERTIBLE NOTES (Details) $ / shares in Units, $ in Thousands	Sep. 03, 2020$ / sharesshares	Dec. 09, 2019$ / sharesshares	Aug. 31, 2019USD ($)	Dec. 31, 2021$ / sharesshares	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)$ / shares	Mar. 11, 2021$ / shares
Convertible Notes (Details) [Line Items]
Convertible notes | $						$ 4,417
Interest expense | $					$ 271	$ 379
Convertible notes issued (in Shares) | shares				2,415,022
Convertible notes (units)			0.142
Convertible notes and warrants total consideration | $			$ 1,420
Convertible notes and warrants consideration per unit (in Dollars per share)				$ 5.06		$ 100	$ 4.60
Discount of warrant			10.00%
Financing expense | $					$ 65
Convertible Notes Related Warrants 2019 [Member]
Convertible Notes (Details) [Line Items]
Convertible notes and warrants consideration per unit (in Dollars per share)	$ 6.72
Warrant excercise | shares	297,589
Warrant [Member]
Convertible Notes (Details) [Line Items]
Convertible notes and warrants consideration per unit (in Dollars per share)		$ 8.80
IPO [Member]
Convertible Notes (Details) [Line Items]
Convertible notes issued (in Shares) | shares	312,170
Convertible notes and warrants consideration per unit (in Dollars per share)	$ 8.80
Warrant term	5 years
Share price per unit (in Dollars per share)	$ 8
Convertible debt conversion price (in Dollars per share)	$ 8.80
Ordinary Shares issued | shares	2,500,000
Warrant expired		Dec. 8, 2024
IPO [Member] | Convertible Notes Related Warrants 2019 [Member]
Convertible Notes (Details) [Line Items]
Convertible notes and warrants consideration per unit (in Dollars per share)		$ 6.72
Ordinary Shares issued | shares		55,785

TAXES ON INCOME (Narrative) (De

TAXES ON INCOME (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Tax Credit Carryforward [Line Items]
Corporate tax rate	23.00%	23.00%	23.00%
Provision for unrecognized tax positions	$ 234	$ 220	$ 0	$ 0
Interest and penalties related to unrecognized tax benefits	9
Accrued interest and penalties	8
Israeli [Member]
Tax Credit Carryforward [Line Items]
Net operating loss carry forwards	$ 19,261	$ 15,114

TAXES ON INCOME (Schedule of De

TAXES ON INCOME (Schedule of Deferred Income Taxes) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating loss carry forward	$ 4,434	$ 3,476
Deferred tax asset before valuation allowance	4,434	3,476
Valuation allowance	(4,434)	(3,476)
Net deferred tax asset	$ 0	$ 0

TAXES ON INCOME (Schedule of Un

TAXES ON INCOME (Schedule of Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Opening balance	$ 220	$ 0	$ 0
Tax positions taken in the current year	0	217	0
Interest	6	3	0
Exchange difference	8	0	0
Closing balance	$ 234	$ 220	$ 0

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	1 Months Ended
	Jul. 26, 2021	Dec. 03, 2020	Dec. 31, 2021	Jan. 12, 2021	Dec. 31, 2020	Dec. 28, 2020	Dec. 10, 2020	Dec. 31, 2019
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Annual rental fee	$ 75,000		$ 33,000		$ 33,000		$ 20,000	$ 33,000
Lessor bank guaranty	$ 16,000
Prepaid clinical trial expenses and deferred clinical trial costs			1,728,000		1,294,000
Deferred clinical trial expense					$ 1,294,000
Clinical trial expense			145,000
First Agreement [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Accumulated payment on clinical research development		$ 2,907,000
Non refundable payment of clinical research and development.						$ 581,000
Aggregate non refundable payment of clinical research and development			581,000
Second Agreement [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Accumulated payment on clinical research development		$ 7,107,000
Non refundable payment of clinical research and development.				$ 710,000
Rita Kenan [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Bonus amount			$ 45

TEMPORARY EQUITY (Narrative) (D

TEMPORARY EQUITY (Narrative) (Details)	Sep. 03, 2020shares
Temporary Equity Disclosure [Abstract]
Outstanding convertible preferred shares	2,954,267

TEMPORARY EQUITY (Schedule of C

TEMPORARY EQUITY (Schedule of Convertible Preferred Shares) (Details) $ in Thousands	Dec. 31, 2019USD ($)shares
Temporary Equity Disclosure [Abstract]
Shares Authorized | shares	18,300,000
Shares Issued and Outstanding | shares	2,954,267
Carrying Value | $	$ 6,621
Liquidation Preference | $	$ 15,250

SHAREHOLDERS' EQUITY (Narrative

SHAREHOLDERS' EQUITY (Narrative) (Details) $ / shares in Units, $ in Thousands	Mar. 11, 2021USD ($)$ / sharesshares	Oct. 05, 2020USD ($)$ / sharesshares	Sep. 03, 2020$ / sharesshares	Jul. 06, 2020	Jul. 02, 2019shares	Jul. 22, 2021USD ($)shares	Feb. 23, 2021$ / sharesshares	May 31, 2021$ / sharesshares	Dec. 31, 2021USD ($)shares	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2021₪ / shares	Dec. 31, 2021USD ($)$ / sharesshares	Jan. 31, 2021$ / shares	Dec. 31, 2020₪ / shares	Dec. 31, 2020USD ($)shares	Oct. 03, 2020$ / shares	Aug. 31, 2020shares	Dec. 09, 2019$ / shares	Dec. 31, 2018shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary share issued													10,482,056			8,758,037
Reverse split				3-for-1
Convertible notes issued (in Shares)									2,415,022
Warrants expired	5 years 6 months
Warrants exercise price | $ / shares	$ 4.60										$ 100		$ 5.06
Outstanding convertible preferred shares			2,954,267
Options granted							300,000	452,020
Per share price | (per share)							$ 4.50	$ 5.74				₪ 0.03		$ 3.01	₪ 0.03
Share-based compensation expense | $									$ 99	$ 18	$ 14
Intrinsic value of share options outstanding | $											$ 275		$ 168			$ 651
Warrants issue to purchase ordinary shares	1,304,346					419,673							3,950,217
Ordinary shares warrants purchase	652,173					419,673			52,173
Gross proceeds from issuance of private placement. | $	$ 6,000
Proceeds from issuance of private placement | $	$ 5,554					$ 1,930
Placement agent fees and other expense | $									$ 500
Private placement fee | $									390
Reimbursement Expense | $									40
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $									713	18
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $									$ 99	$ 18
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted							60,000
2008 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding											153,882		153,882			153,882
2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term plan					10 years
Reserve for issuance					971,476
Options outstanding											219,456		971,476			219,456				0
Options granted									752,020	0	219,456
Option expired									0	0	0
Intrinsic value of share options outstanding | $													$ 224			$ 407
Intrinsic value of share options exercisable | $													$ 224			$ 385
Convertible Notes Related Warrants 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares			$ 6.72
Warrant excercise			297,589
IPO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Convertible notes issued (in Shares)			312,170
Warrants expired			5 years
Warrants exercise price | $ / shares			$ 8.80
IPO [Member] | Convertible Notes Related Warrants 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares																			$ 6.72
Over-Allotment Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant excercise			375,000
Per share price | $ / shares			$ 0.01
Warrants issue to purchase ordinary shares		375,000
Proceeds from issuance of private placement | $		$ 3
Crescendo Communications [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary share issued																		152,110
Percentage of shares issued																		3.75%
Share-based compensation expense | $									$ 412	$ 137
Underwriters [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares		$ 8.80
Warrant excercise		375,000
Warrant expired date		Sep. 3, 2025
Amount of return | $		$ 3
Underwriters [Member] | IPO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants expired			5 years
Options granted			125,000
Per share price | $ / shares			$ 10														$ 10
Offering price			125.00%

SHAREHOLDERS' EQUITY (Schedule

SHAREHOLDERS' EQUITY (Schedule of Warrants and Warrants Units Outstanding) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Jul. 22, 2021	Mar. 11, 2021	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Number of warrants	3,950,217	419,673	1,304,346
Exercise price	$ 5.06		$ 4.60	$ 100
August 2019 warrants [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Aug. 22, 2019
Number of warrants	205,268
Exercise price	$ 6.72
Exercisable through	Aug. 22, 2024
December 2019 warrants [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Dec. 9, 2019
Number of warrants	92,321
Exercise price	$ 6.72
Exercisable through	Dec. 8, 2024
Warrants to 2019 convertible notes placement agent (Member)
Class of Warrant or Right [Line Items]
Issuance Date	Dec. 9, 2019
Number of warrants	55,785
Exercise price	$ 6.72
Exercisable through	Dec. 8, 2024
Warrants To Underwriter [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Sep. 3, 2020
Number of warrants	125,000
Exercise price	$ 10
Exercisable through	Sep. 1, 2025
Warrants To Underwriters [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Oct. 5, 2020
Number of warrants	375,000
Exercise price	$ 8.80
Exercisable through	Sep. 3, 2025
Ipo Warrants [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Sep. 3, 2020
Number of warrants	2,812,170
Exercise price	$ 8.80
Exercisable through	Sep. 3, 2025
PIPE warrants [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Mar. 11, 2021
Number of warrants	232,500
Exercise price	$ 4.60
Exercisable through	Sep. 10, 2026
Warrants to PIPE placement agent [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Mar. 11, 2021
Number of warrants	52,173
Exercise price	$ 5.06
Exercisable through	Mar. 8, 2026

SHAREHOLDERS' EQUITY (Schedul_2

SHAREHOLDERS' EQUITY (Schedule of share options outstanding and exercisable under 2008 Plan) (Details) - $ / shares	1 Months Ended	5 Months Ended	12 Months Ended
	Feb. 23, 2021	May 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of options
Granted	300,000	452,020
2008 Plan [Member]
Number of options
Options outstanding		153,882	153,882	153,882
Options outstanding			153,882	153,882	153,882
Exercisable at the end of the year			153,882
Weighted-average exercise price
Outstanding at the beginning of the year		$ 0.24	$ 0.24	$ 0.24
Outstanding at the end of the year				$ 0.24	$ 0.24
Exercisable at the end of the year			$ 0.24
Weighted-average remaining contractual term
Outstanding at the beginning of the year			2 years 3 months	3 years 3 months	4 years 3 months
Exercisable at the end of the year			2 years 3 months

SHAREHOLDERS' EQUITY (Schedul_3

SHAREHOLDERS' EQUITY (Schedule of assumptions used for fair value of options) (Details) - 2019 Plan [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rates		0.00%
Volatility		0.00%
Dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	5 years 10 months 9 days		5 years 9 months
Risk-free interest rates	0.52%		1.43%
Volatility	69.67%		82.29%
Exercise price	$ 3.013		$ 0.24
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	6 years 1 month 9 days		10 years
Risk-free interest rates	1.13%		2.13%
Volatility	78.99%		85.56%
Exercise price	$ 5.738		$ 3.339

SHAREHOLDERS' EQUITY (Schedul_4

SHAREHOLDERS' EQUITY (Schedule of Stock Option Activity) (Details) - $ / shares	1 Months Ended	5 Months Ended	12 Months Ended
	Feb. 23, 2021	May 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of options
Granted	300,000	452,020
2019 Plan [Member]
Number of options
Options outstanding		219,456	219,456	219,456	0
Granted			752,020	0	219,456
Forfeited			0	0	0
Exercised			0	0	0
Options outstanding			971,476	219,456	219,456
Exercisable at the end of the year			361,280	200,269	156,386
Weighted-average exercise price
Outstanding at the beginning of the year		$ 2.62	$ 2.62	$ 2.62	$ 0
Granted			5.07	0	2.62
Forfeited			0	0	0
Exercised			0	0	0
Outstanding at the end of the year			4.51	2.62	2.62
Exercisable at the end of the year			$ 3.58	$ 2.55	$ 2.77
Employees and Directors [Member] | 2019 Plan [Member]
Number of options
Options outstanding		219,456	219,456
Granted			752,020
Options outstanding			971,746	219,456
Exercisable at the end of the year			361,280
Weighted-average exercise price
Outstanding at the beginning of the year		$ 2.62	$ 2.62
Granted			5.06
Outstanding at the end of the year			4.51	$ 2.62
Exercisable at the end of the year			$ 3.58
Weighted-average remaining contractual term
Outstanding at the beginning of the year			8 years 8 months 19 days	8 years 6 months 21 days
Granted			9 years 18 days
Exercisable at the end of the year			8 years 1 month 20 days

SELECTED STATEMENTS OF OPERAT_3

SELECTED STATEMENTS OF OPERATIONS DATA (Schedule of Research and Development Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Financial Expenses Net [Abstract]
Subcontractors and consultants	$ 1,654	$ 217	$ 21
Payroll and related expenses	719	90	59
Share-based compensation expense	99	18	14
Clinical trials expenses	357	0	0
Other expenses	31	29	42
Total Research and development expenses	$ 2,860	$ 354	$ 136

SELECTED STATEMENTS OF OPERAT_4

SELECTED STATEMENTS OF OPERATIONS DATA (Schedule of General and Administrative Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Financial Expenses Net [Abstract]
Professional services	$ 1,697	$ 727	$ 342
Payroll and related expenses	688	154	60
D&O insurance	935	360	0
Rent and office maintenance	210	37	33
Share-based compensation expense	713	20	75
Others	105	19	43
Total General and administrative expenses	$ 4,348	$ 1,317	$ 553

SELECTED STATEMENTS OF OPERAT_5

SELECTED STATEMENTS OF OPERATIONS DATA (Schedule of Financial Expenses, Net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Financial Expenses Net [Abstract]
Interest expense and amortization of discount on convertible notes	$ 0	$ 987	$ 541
Issuance expenses	0	65	47
Bank fees	10	3	2
Change in fair value of derivative warrant liability	0	1,105	2
Exchange rate differences	22	2	(2)
Total financial expenses, net	$ 32	$ 2,162	$ 590

RELATED PARTIES BALANCES AND _3

RELATED PARTIES BALANCES AND TRANSACTIONS (Details) - USD ($)	1 Months Ended		5 Months Ended	12 Months Ended
	Feb. 23, 2021	Jan. 26, 2020	May 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jul. 26, 2021	Dec. 10, 2020
Related Party Transaction [Line Items]
Convertible notes						$ 4,417,000
Rental properties				$ 33,000	$ 33,000	33,000	$ 75,000	$ 20,000
Management fee				20,000
Operating lease provided by controlling shareholder				$ 0	$ 33,000	25,000
Options granted	300,000		452,020
Director [Member]
Related Party Transaction [Line Items]
One time payment		$ 150,000
Board of Directors Chairman [Member]
Related Party Transaction [Line Items]
One time payment, quarterly basis		$ 37,500
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Options granted	60,000
Three board members, Chairman of the board of directors and to its Chief Technology Officer [Member]
Related Party Transaction [Line Items]
Options granted	300,000
Shareholder [Member]
Related Party Transaction [Line Items]
Convertible notes						$ 95,000
Convertible notes annual interest rate						8.00%

RELATED PARTIES BALANCES AND _4

RELATED PARTIES BALANCES AND TRANSACTION ( Schedule of Balances and Transactions with Related Parties ) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
Employees accrued salaries	$ 356	$ 79
Directors accrued expenses	82	35
Employees and directors expense	$ 438	$ 114

RELATED PARTIES BALANCES AND _5

RELATED PARTIES BALANCES AND TRANSACTIONS (Schedule of Balances and Transactions with Related Parties) (Details1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Amounts charged to
Research and development expenses	$ 151	$ 0	$ 0
General and administrative expenses	2,155	370	210
Interest expense on convertible notes	$ 0	$ 251	$ 351